The landscape of pharmacological obesity treatment has shifted so rapidly that clinicians and patients alike face a genuinely difficult question: among a growing roster of injectable and oral agents, which options deliver the most meaningful, and safest, results? A comprehensive synthesis published in the BMJ now offers the most rigorous comparative picture to date, drawing on evidence from nearly 100,000 participants across 262 randomized controlled trials.
The analysis evaluated 19 drugs across 24 outcomes, applying GRADE certainty ratings and Bayesian dose-response modeling alongside frequentist network meta-analysis — a methodological combination that strengthens confidence in the rank ordering. At the one-year mark, tirzepatide (a dual GIP/GLP-1 receptor agonist) and the investigational combination cagrilintide-semaglutide, known as CagriSema, led all agents with mean body weight reductions of approximately 14.9% and 14.8% respectively versus lifestyle modification alone, both supported by moderate-to-high certainty evidence. Oral semaglutide, orforglipron — a promising non-peptide oral GLP-1 receptor agonist — and subcutaneous semaglutide clustered in a second tier around 9.8–10.9% reduction. Older agents including phentermine-topiramate showed more modest but still meaningful effects near 8%. Emerging pipeline drugs such as retatrutide and mazdutide showed signals of potentially superior efficacy, though certainty remains very low to low.
This study is arguably the most practically useful comparative effectiveness resource on obesity pharmacotherapy published to date, given its scope, GRADE grading, and inclusion of safety outcomes. Several important caveats temper the findings: follow-up rarely exceeded 172 weeks, most trials were industry-funded, and network meta-analysis assumes transitivity across trial populations that may differ meaningfully in baseline characteristics. The absence of long-term cardiovascular mortality data for several newer agents also limits clinical translation. Still, the clear stratification of efficacy — with dual and triple receptor agonists outperforming single-mechanism GLP-1 agents — provides a mechanistically coherent picture that aligns with the emerging pharmacology of incretin-based obesity treatment. This qualifies as a potentially paradigm-shaping synthesis for prescribers navigating an increasingly complex formulary.